Ionis EVP Bennett buys 110 shares at $51.31

Ionis Pharmaceuticals’ chief scientific officer bought shares through the employee stock purchase plan, increasing his direct holdings to 60,128 shares with a lock-up into 2027.

Rhea-AI Filing Summary

IONIS PHARMACEUTICALS INC executive Frank C. Bennett, EVP and Chief Scientific Officer, reported acquiring 110 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $51.306 per share. After this purchase, he directly holds 60,128 shares of Ionis common stock. The filing states these purchased shares may not be sold until February 28, 2027, and no Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Other: 110 shares

Other 1 txn

Insider BENNETT C FRANK

Role EVP, Chief Scientific Officer

Type	Security	Shares	Price	Value
Other	Common Stock F1	110	$51.306	$6K

Holdings After Transaction: Common Stock — 60,128 shares (Direct)

Footnotes (1)

1. F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Key Figures

Shares acquired: 110 shares Purchase price per share: $51.306 per share Post-transaction holdings: 60,128 shares +2 more

5 metrics

Shares acquired 110 shares Common stock acquired on August 31, 2026 under the employee stock purchase plan

Purchase price per share $51.306 per share Price for the 110 shares purchased on August 31, 2026

Post-transaction holdings 60,128 shares Direct common stock holdings of Frank C. Bennett after the reported transaction

Sale restriction end date February 28, 2027 Date after which the 110 purchased shares may be sold

Transaction date August 31, 2026 Date of the employee stock purchase plan acquisition

Key Terms

Amended and Restated 2000 Employee Stock Purchase Plan, Employee Stock Purchase Plan

2 terms

Amended and Restated 2000 Employee Stock Purchase Plan financial

"Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026."

Employee Stock Purchase Plan financial

"Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

What insider transaction did Ionis Pharmaceuticals (IONS) report for Frank C. Bennett?

Ionis Pharmaceuticals reported that Frank C. Bennett, EVP and Chief Scientific Officer, acquired 110 shares of common stock on August 31, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan.

At what price were the new IONS shares acquired by the executive?

The 110 Ionis Pharmaceuticals shares were purchased at a price of $51.306 per share under the company’s Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026.

How many Ionis Pharmaceuticals (IONS) shares does Frank C. Bennett hold after this transaction?

Following the reported purchase, Frank C. Bennett directly holds 60,128 shares of Ionis Pharmaceuticals common stock.

Are the newly purchased IONS shares immediately saleable by the executive?

No. The filing states that the 110 shares purchased under the Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026 may not be sold until February 28, 2027.

Was the Ionis Pharmaceuticals (IONS) insider trade made under a Rule 10b5-1 plan?

The filing indicates that no Rule 10b5-1 trading plan is reported for this transaction; the document-level trading plan checkbox is not marked as being made under such a plan.

What role does the reporting person hold at Ionis Pharmaceuticals (IONS)?

The reporting person, Frank C. Bennett, serves as Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 08:33 PM Accepted by SEC EDGAR 09/02/2026 - 08:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENNETT C FRANK

(Last) (First) (Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD CALIFORNIA 92010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		J		110(1)	A	$51.306	60,128	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

	By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)